Evommune, Inc. (EVMN)
Quote, stock score, analyst consensus, and SEC filings, plus insider and Congress trades when there are any.
NYSE · Price as of · Nasdaq Real Time Price
- Analysts9
- Implied upside+254.8%
- Target range$8.00 to $30.00
- EPS expected-$0.83
- A year ago-$8.07
- Estimate range-$1.02 to -$0.67
SEC filings
| Form | Filed | Description |
|---|---|---|
| 4 | October 15, 2026 | PRIMARY DOCUMENT |
| 8-K | October 1, 2026 | 8-K |
| 8-K | September 23, 2026 | 8-K |
| 8-K | September 15, 2026 | 8-K |
| 424B3 | September 9, 2026 | 424B3 |
| 8-K | September 9, 2026 | 8-K |
| SCHEDULE 13G/A | August 14, 2026 | View on EDGAR |
| SCHEDULE 13G | August 14, 2026 | View on EDGAR |
Articles that mention Evommune without it being the main subject.
Frequently asked questions
When does EVMN report earnings?
Evommune, Inc. (EVMN) is scheduled to report quarterly results on November 16, 2026 (estimated). The 11-analyst consensus is -$0.83 per share for the quarter ended September 30, 2026, against -$8.07 a year earlier. The date is an estimate from past reporting patterns and can move until the company confirms it.
What do analysts expect for EVMN?
9 analysts cover Evommune, Inc. (EVMN). The consensus rating is Buy. The average price target is $22.33, in a range of $8.00 to $30.00.
Are insiders buying or selling EVMN?
We have no qualifying Form 4 insider purchases or sales on record for Evommune, Inc. (EVMN). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see EVMN SEC filings?
Recent filings are listed on this page, newest first. The latest is a 4 filed October 15, 2026.